(Total Views: 191)
Posted On: 09/11/2017 5:30:13 PM
Post# of 72441
I think that Prurisol is the most likely candidate for a first deal, assuming it works as well on humans as it did on critters.
Brilacidin has the most potential to treat MANY different conditions so it is most likely the most valuable property. (Unless, of course, Kevetrin proves to be a non-toxic cure for cancer, in which case it would be incredibly valuable.) So it would be smart to hold off on a deal for Bril, to maximize the payment to the company and thus to shareholders.
It still amazes me that CTIX/IPIX bought the rights to Brilacidin for 5 million bucks. AXON paid 5 million bucks for the rights to a failed Alzheimer's drug that they are trying to make work (even though it's going down the same failed pathway as all the other Alz drugs) -- and their market cap is 2 Billion with a B.
What's wrong with this picture?
Brilacidin has the most potential to treat MANY different conditions so it is most likely the most valuable property. (Unless, of course, Kevetrin proves to be a non-toxic cure for cancer, in which case it would be incredibly valuable.) So it would be smart to hold off on a deal for Bril, to maximize the payment to the company and thus to shareholders.
It still amazes me that CTIX/IPIX bought the rights to Brilacidin for 5 million bucks. AXON paid 5 million bucks for the rights to a failed Alzheimer's drug that they are trying to make work (even though it's going down the same failed pathway as all the other Alz drugs) -- and their market cap is 2 Billion with a B.
What's wrong with this picture?
(1)
(0)Scroll down for more posts ▼
